anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: ethylic dihydroquercetin consisting of mixed bioflavonoids, is pre-heated, passed through a baromembrane filter and through a coal absorptive layer with electrochemical potential, watered and exposed to recrystallisation. After watering, a filtrate is cooled to +10C12C and passed through the magnetic field generated by the same constant magnet poles, and when passing through the baromembrane filter, the solution is exposed to the polarising field. When passing through the coal absorptive layer, the solution is exposed to the low-voltage and low-current DC electric field, and the filtrate is diluted with deionised water in the ratio 1:2. The product is crystallised under vacuum at temperature below -20C. 3. A device for dihydroquercetin purification includes a feed pump and a heater of ethylic dihydroquercetin, the baromembrane filter, the coal absorptive layer, a water feeder and a crystalliser. ^ EFFECT: invention allows for higher product yield. ^ 4 cl, 1 tbl, 1 dwg
Schizophrenia is a disabling mental disorder that can interfere with a person's ability to function both alone and in social situations. Various treatments have been effective in treating schizophrenia, including antipsychotic medications and cognitive therapy. Psychosocial skills training, a type of cognitive therapy, is often used to help people with schizophrenia cope with their condition and improve social functioning in day-to-day life. However, many individuals with schizophrenia experience difficulty paying attention, and this is a significant barrier to successful outcomes in psychosocial skills training interventions. Attention shaping procedures (ASP) is a behavioral intervention that helps individuals with impaired attention capacities to benefit from skills-based treatment. This study will evaluate the effectiveness of ASP in improving attentiveness and learning abilities in people undergoing psychosocial skills training treatment for schizophrenia.

Participants in this 5-month, single-blind study will be randomly assigned to ASP plus basic conversation skills training (BCS), which is a social skills training group, or BCS alone. Training sessions for both groups will be held when participants attend regular hospital visits. During the first month, participants will complete two sessions of interviews, self-report scales, and social and cognitive functional assessments. Over the next 3 months, training sessions for both groups will occur twice a week for approximately 1 hour. ASP sessions will focus on setting goals and increasing the quality and duration of participants' attentiveness during psychosocial interventions. BCS will train participants in the following five skill areas: recognizing verbal and non-verbal cues; starting a friendly conversation; keeping conversation going; ending a conversation politely; and incorporating all of these skills together. During the last month, participants will attend two interview sessions lasting approximately 4 hours each. One follow-up session will occur 6 months after completing the intervention.
Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe cyclosporine capsules, (NON-MODIFIED). Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

Cyclosporine capsules, (NON-MODIFIED) should be administered with adrenal corticosteroids but not with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression.

Cyclosporine capsules, (NON-MODIFIED) have decreased bioavailability in comparison to Neoral®* (cyclosporine capsules, USP) MODIFIED.

Cyclosporine capsules, (NON-MODIFIED) and Neoral®* (cyclosporine capsules, USP) MODIFIED are not bioequivalent and cannot be used interchangeably without physician supervision.

The absorption of cyclosporine during chronic administration of cyclosporine capsules, (NON-MODIFIED) was found to be erratic. It is recommended that patients taking cyclosporine capsules, (NON-MODIFIED) over a period of time be monitored at repeated intervals for cyclosporine blood concentrations and subsequent dose adjustments be made in order to avoid toxicity due to high concentrations and possible organ rejection due to low absorption of cyclosporine. This is of special importance in liver transplants. Numerous assays are being developed to measure blood concentrations of cyclosporine. Comparison of concentrations in published literature to patient concentrations using current assays must be done with detailed knowledge of the assay methods employed (see  DOSAGE AND ADMINISTRATION,  Blood Concentration Monitoring).
This is a randomized controlled trial comparing the use of i-scan (digital surface and contrast enhancement of the mucosa) versus standard high-definition white light for the detection of conventional adenomas and sessile serrated adenomas/polyps. Recent studies have indicated that colonoscopy is more effective in preventing cancer in the left side of the colon than the right side of the colon. The reasons for this difference may be partly biologic, in that a special group of polyps known as sessile serrated adenomas/polyps (SSA) are located primarily proximal to the splenic flexure. Sessile serrated adenomas/polyps share molecular features with a group of cancers that occur primarily in the proximal colon. These molecular features include CpG island methylator phenotype (CIMP) and microsatellite instability. These lesions are endoscopically subtle in that they are often flat, have the same color as the surrounding mucosa, and are hard to differentiate from normal mucosa. Recent studies have shown that image enhanced endoscopy can highlight the appearance of these lesions. This study will test whether i-scan increases the detection of conventional adenomas and sessile serrated adenomas/polyps in a randomized controlled trial.
Usual care for first three months. Initiation of the eCMP after the 3-month time point.
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
The invention belongs to a traditional Chinese medicine, and in particular relates to a traditional Chinese medicine for treating lithangiuria. The traditional Chinese medicine is characterized by being prepared from the following components in parts by weight: 110g to 130g of portulaca oleracea, 50g to 70g of honeysuckle and 80g to 100g of brown sugar. After medicine residues are removed, 400ml of medicine juice is taken while being hot; then a patient is shielded by a quilt until sweating. One dose of medicine juice is decocted every time and is taken thrice everyday. The lithangiuria is lightened after the medicine juice is taken for 1 to 3 days, and can be cured after the medicine juice is continuously taken for 7 to 15 days for consolidation treatment. According to the traditional Chinese medicine syndrome differentiation theory, the traditional Chinese medicine is simple in formula, low in cost, high in treatment effect and free of toxic and side effect, and can be used for effectively treating the lithangiuria, and the materials are easily available.
BACKGROUND: The common hepatic artery lymph node (CHALN) represents a second-echelon node for tumors in the head of the pancreas. Although early studies suggested survival was comparable between the CHALN and remote metastasis in pancreatic ductal adenocarcinoma (PDAC), whether the lymph node is associated with adverse survival remains equivocal. Here, we examined a prospective cohort of patients calculating actual survival to better understand implications of this specific lymph node metastasis.
METHODS: We studied 215 patients with pancreatic head PDAC, who underwent pancreaticoduodenectomies at a single institution between 2010 and 2017, wherein the CHALNs were excised. We performed actual and actuarial overall survival and disease-free survival (DFS) analyses, with subsequent univariate and multivariate analyses in node-positive patients.
RESULTS: Of this cohort, 7.3% of patients had involvement of the CHALN, and all of them had metastatic spread to first-echelon nodes. Actual median survival of patients with no lymph node involvement was 49 months. In patients with any nodal involvement, the survival was no different when comparing the lymph node positive and negative (13 and 20 months, respectively). Univariate and multivariate analyses likewise attached no significance to the lymph node metastasis, while demonstrating worse survival with positive margin status and poorly differentiated histology. Our DFS analyses yielded similar results.
CONCLUSION: We found no difference in actual survival in node-positive patients regardless of the CHALN involvement and recommended against its assessment in prognosticating survival or guiding surgical treatment.
Angiogenesis is crucial for blood supply reconstitution after myocardial infarction in patients with acute coronary syndrome (ACS). MicroRNAs are recognized as important epigenetic regulators of endothelial angiogenesis. The purpose of this study is to determine the roles of miR-522-3p in angiogenesis after myocardial infarction. The expression levels of miR-522-3p in rats' plasma and in the upper part of the ligation of the heart tissues at 28 days after myocardial infarction were significantly higher than those of the sham group. miR-522-3p mimics inhibited cell proliferations, migrations, and tube formations under hypoxic conditions in HUVECs (human umbilical vein endothelial cells), whereas miR-522-3p inhibitors did the opposite. Furthermore, studies have indicated that the inhibition of miR-522-3p by antagomir infusion promoted angiogenesis and accelerated the recovery of cardiac functions in rats with myocardial infarction.Data analysis and experimental results revealed that FOXP1 (Forkhead-box protein P1) was the target gene of miR-522-3p. Our study explored the mechanism of cardiac angiogenesis after myocardial infarction and provided a potential therapeutic approach for the treatment of ischemic heart disease in the future.
Class IIa histone deacetylases (Class IIa HDACs) play critical roles in regulating essential cellular metabolism and inflammatory pathways. However, dissecting the specific roles of each class IIa HDAC isoform is hindered by the pan-inhibitory effect of current inhibitors and a lack of tools to probe their functions beyond epigenetic regulation. In this study, a novel PROTAC-based compound B4 is developed, which selectively targets and degrades HDAC7, resulting in the effective attenuation of a specific set of proinflammatory cytokines in both lipopolysaccharide (LPS)-stimulated macrophages and a mouse model. By employing B4 as a molecular probe, evidence is found for a previously explored role of HDAC7 that surpasses its deacetylase function, suggesting broader implications in inflammatory processes. Mechanistic investigations reveal the critical involvement of HDAC7 in the Toll-like receptor 4 (TLR4) signaling pathway by directly interacting with the TNF receptor-associated factor 6 and TGFβ-activated kinase 1 (TRAF6-TAK1) complex, thereby initiating the activation of the downstream mitogen-activated protein kinase/nuclear factor-κB (MAPK/NF-κB) signaling cascade and subsequent gene transcription. This study expands the insight into HDAC7's role within intricate inflammatory networks and highlights its therapeutic potential as a novel target for anti-inflammatory treatments.
Participants will be instructed to follow a 16/8 regimen characterized by 16 hours of fasting and an 8-hour eating window daily, on approximately 5 days/week, for 3 months. Previous research has shown that 16 hours of fasting is feasible, safe and well-tolerated among older adults, and that most persons report easy adjustment (Anton, Lee et al. 2019, Lee, Sypniewski et al. 2020). The intervention will be implemented through individual and group sessions with participants and will involve extensive education, coaching, guidance, and support throughout the 3-month intervention. Educational materials on lifestyle factors including physical activity will be provided to each participant. We will be also be collecting data on physical activity and sedentary behavior. These data will be co-variates when we conduct the statistical analysis.
This is a multi-country, multi-center, observational, prospective study involving primary data collection within real-world pulmonary care settings for patients who receive benralizumab treatment for severe uncontrolled eosinophilic asthma.The decision by the physician to start benralizumab is made independently from study inclusion and patient informed consent. Patients will receive benralizumab injections according to the local label in the participating countries (Brazil, Argentina, Colombia, India, and the Gulf cooperative council, including the Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Oman, and Qatar). No study drug will be provided as part of the study. The entire study period duration will be 56 weeks for each subject. The study is anticipated to run for approximately 18 months and is not anticipated to exceed 24 months. A database soft lock is planned at the end of the initial 8-week period of the study, and one combined descriptive and analytical interim analysis will be performed when 50% of the enrolled subjects complete the 8-week follow-up.
One half (54) of the identified cases were randomized to receive the previously established "BREATHE" study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted.
In current stone guidelines, the recommendations for stone therapy in the kidneys with normal anatomy are clearly stated; however, there is also no clear suggestion and treatment modality in regards to the stone treatment in anomalous kidneys. Nowadays, open surgery, percutaneous nephrolithotomy (PNL), SWL, and RIRS are used for the treatment of these kidney stones. However, there is no clear consensus on which treatment modalities should be used; each modality has its unique advantages and drawbacks. in this study, the investigators will prospectively evaluate the safety and efficacy of RIRS in treatment of stones in kidneys with rotation or position anomalies. The investigators will compare the results with a matched group of patients who were treated with SWL. The results of this study may help clarify treatment options in the management of patients with stones and renal anomalies.
Pregnancy Category C

Calcium acetate capsules contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see Warnings and Precautions (5.1)]. Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.
FIELD: medicine, gastroenterology. SUBSTANCE: invention relates to methods of treatment and drugs based on bifidobacteria. Method of treatment involves administration of preparation of bifidobacteria in their amount 0.6-1.0 g in 5-5000 mln of cells in the following schedule: 4-40 g in the first 24 h; 4-12 g in 12 h; 4-18 g in the 48 h; one dose 4-12 g in the 72 h; 3-9 g in the 96 h and in the following days. Remedy has the following components in the definite ratio: viable bifidobacterium cells, bifidogenic component, immobilizing agent, gelatin and sucrose. EFFECT: enhanced effectiveness of bifidobacteria, decreased time of treatment. 6 cl, 3 ex
FIELD: medicine.SUBSTANCE: method involves the nasoenteric administration ofTc-pertechnetate into a small intestine at 1.0-14 MBq/kg diluted with normal saline to an amount of 20 ml. That is immediately followed by a dynamic scintigraphy by means of two-detector rotation gamma-chamber for 60 minutes with a gamma-chamber detection mounted above a projection of the intestine and liver. Following the examination results enables calculated an absorption coefficient of a radiopharmaceutical agent (K); thereafter the scintigraphy is continued in the mode of "The Whole Body", which provides a basis to determine a percentage of the radiopharmaceutical agent (A) absorbed from an intestinal lumen. If the absorption coefficient is less than 3 and the absorption is less than 50% from the administered radiopharmaceutical agent, the small intestinal malabsorption is stated. K is described by the scintigram forming the sharpest image of the liver and having an area of interest 100 pxls to be marked within a liver, which is followed by constructing an activity/time curve. K is calculated as a slope of the curve to a horizontal axis with using the first 4 minutes of the linear rise of the curve by formula: K=(y-y)/(t-t)×60, wherein K is the absorption coefficient, tand tare time distances, seconds; yis a pulse count within the time distance t, yis a pulse count within the time distance t. To calculate A, an area including the whole patient's body and an area covering the visualised enteric loops are marked on the scintigram. The calculation follows the formula: A=(n(b)-n(e))/n(e)×100%, wherein n(b) is the total pulse count recorded within the whole body; n(e) is the total pulse count recorded within the small intestine.EFFECT: method provides the high information value of the examination ensured by the complex analysis of the enteric function parameters in the early postoperative period.3 cl, 3 dwg, 1 ex
The present invention relates to a ganoderma lucidum chewable tablet and a preparation method thereof. The chewable tablet is prepared from active constituents which are extracted from ganoderma lucidum, cyclodextrin and proper auxiliary material. The present invention has the efficacy of tranquilizing the heart, calming mind, strengthening the spleen and harmonizing the stomach, and is used for the pathological symptoms of insomnia, amnesia, weak body, neurasthenia, etc. In the present invention, bitter triterpene substances are separated from ganoderma lucidum by an ethanol separation technique, the triterpene substances, etc. of the ganoderma lucidum are clathrated in cyclodextrin molecules by a cyclodextrin clathration technique, and the problem that the chewable tablet which is prepared by the ganoderma lucidum has bitter taste is solved. Compared with the prior art, the medicine of the present invention has the advantages of convenient administration, no influence on therapeutic effect, good mouth feel, rapid dissolution and absorption, high bioavailability, little possibility of moisture absorption and deterioration, stable quality, etc.
OBJECTIVES: I. Define the maximum tolerated dose of COL-3 in patients with advanced solid tumors. II. Identify the dose limiting toxicity and safety profile of COL-3 in these patients. III. Define the pharmacokinetics and pharmacodynamics of COL-3 in these patients. IV. Observe any evidence of antitumor activity through standard response criteria or biologic surrogate markers.

OUTLINE: This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.

PROJECTED ACCRUAL: Up to 30 patients will be accrued within 1 year for this study.
A method for diagnosing a health state of a mobile terminal user, a device, and a system therefor are provided to capture voice data pronounced by a user of a mobile device, and to extract feature values of the user's voice from the captured data, thereby determining health information on the user by analyzing the feature values. A microphone(210) receives a user's voice. A voice analyzer(218) extracts feature values from the user's voice, and analyzes the user's voice. The user's health state information is determined on the basis of the extracted feature values. A health management module(222) determines the user's health state information by receiving the extracted feature values. A memory(216) stores normal feature values corresponding to the user's normal health state. A health management module(232) evaluates the health sate of the user based on the information accumulated at a health state database(234).
Objective:To explore the correlation between the parameters of suppression head impulse paradigm(SHIMP) and changes in dizziness handicap inventory(DHI) scores. Additionally, to evaluate the degree of vertigo and prognosis of patients with acute vestibular neuritis through SHIMP parameters. Methods:Thirty-three patients with acute vestibular neuritis were enrolled for DHI evaluation, vHIT and SHIMP. A secondary DHI score were evaluated after after two weeks, once patients no longer exhibited spontaneous nystagmus. The decrease in the second DHI score was used as the efficacy index(EI). All patients were divided into significantly effective group, effective group and ineffective group based on EI. Differences of the VOR gain values of SHIMP and the anti-compensatory saccade were compared among the three groups. Results:There were 13 cases in the significant effective group, 11 cases in the effective group, and 9 cases in the ineffective group. ①The mean gain of the horizontal semicircular canal in the significant effective group, the effective group, and the ineffective group was(0.50±0.11), (0.44±0.12), and(0.34±0.08), respectively. The difference between the significant effective group and the ineffective group was statistically significant(P<0.01). The gain of horizontal semicircular canal was positively correlated with EI(r=0.538 5, P<0.01) 。②The occurrence rate of the anti-compensatory saccade in the significant effective group, the effective group, and the ineffective group was(51.23±19.59), (33.64±17.68), and(13.78±11.81), respectively. Pairwise comparisons between each group showed statistical significance(P<0.05). The occurrence rate of anti-compensatory saccade was positively correlated with EI(r=0.658 2, P<0.01). Conclusion:The horizontal semicircular canal gain and the occurrence rate of the anti-compensatory saccade in SHIMP for patients with acute vestibular neuritis were closely correlated with decrease in DHI score.